Evidence map›Paper›PMID 40814599›Full record

ArticleKidney international reports2025

Impact of Improved Diagnosis and Treatment on Holistic CKD Burden.

Navdeep Tangri, Stacey Priest, Anthony Zara, Bo Ren Long, Jieling Chen, Naveen Rao, Clélia-Elsa Froguel, Breonny Robson, Nick Guldemond, Matthew Eckelman and 6 more

Abstract read
In one paragraph

Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Navdeep TangriUniversity of Manitoba, Winnipeg, Manitoba, Canada.
Stacey PriestDepartment of Value & Evidence, EVERSANA, Burlington, Ontario, Canada.
Anthony ZaraDepartment of Value & Evidence, EVERSANA, Burlington, Ontario, Canada.
Bo Ren LongDepartment of Value & Evidence, EVERSANA, Burlington, Ontario, Canada.
Jieling ChenBioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
Naveen RaoBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Clélia-Elsa FroguelBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Breonny RobsonKidney Health Australia, Melbourne, Victoria, Australia.
Nick GuldemondLeiden University Medical Centre, Leiden, The Netherlands.
Matthew EckelmanDepartment of Civil & Environmental Engineering, Northeastern University, Boston, Massachusetts, USA.
Ana Flavia MouraEscola Bahiana de Medicina e Saúde Pública, Salvador, Brazil.
Ralph AudehmDepartment of General Practice, University of Melbourne, Melbourne, Australia.
Fiona AdsheadSustainable Healthcare Coalition, Devon, UK.
Ming-Hui ZhaoRenal Division, Peking University First Hospital Peking University Institute of Nephrology Beijing, People's Republic of China.
Christoph WannerDivision of Nephrology, University Hospital of Würzburg, Würzburg, Germany.
Steven ChadbanRoyal Prince Alfred Hospital, Camperdown, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic kidney disease (CKD) is an underdiagnosed and undertreated disease despite the availability of effective interventions. The potential clinical, economic, and environmental impacts of increased diagnosis and improved adherence to guideline-directed medical therapies (GDMTs) recommended for patients with CKD are not well-understood. Methods: Eight country populations (Australia, Brazil, China, Germany, The Netherlands, Spain, UK, and USA) were simulated for 25 years using the IMPACT CKD model to compare burdens under various diagnosis and GDMT adherence scenarios versus current practice. GDMT consisted of kidney protecting, glucose lowering, lipid lowering, as well as antihypertensive and lifestyle interventions. Patients could be treated with 1 or multiple therapies, if eligible, and no guideline changes occurred over the time horizon. Treatment effects were assumed multiplicative. Results: Scenarios with improved GDMT adherence projected cumulative decreases in dialysis, cardiovascular (CV) events, and death by -3.2% to -23.2%, -12.2% to -41.4%, and -2.3% to -9.3%, respectively, compared with current practice over 10 years. Because of delayed CKD progression, kidney replacement therapy (KRT) costs and environmental burden were also projected to decrease by -2.5% to -19.4% and -2.7% to -21.2%, respectively, compared with current practice. All treatment scenarios predicted greater improvements over 25 years, underscoring the long-term impact of CKD, and highlighting the importance of early intervention. Conclusion: Differences in projected impacts between countries are multifactorial, though they are sensitive to demographics and health care systems. Implementation of policies that lead to improved detection and treatment of CKD are urgently required across the globe to mitigate the growing burdens of CKD on patients and caregivers, health care systems, society, and our environment.

Indexed as

chronic kidney diseasedisease burdenguideline directed medical therapyhealth policy modelkidney replacement therapytargeted screening

Identifiers

PMID40814599
PMCPMC12348058

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.